Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
about
Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside.Anti-GD2 immunotherapy for neuroblastoma.Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.Neuroblastoma: clinical and biological approach to risk stratification and treatment.CAR T Cell Therapy for Neuroblastoma
P2860
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Irinotecan-temozolomide with t ...... el, randomised, phase 2 trial.
@ast
Irinotecan-temozolomide with t ...... el, randomised, phase 2 trial.
@en
type
label
Irinotecan-temozolomide with t ...... el, randomised, phase 2 trial.
@ast
Irinotecan-temozolomide with t ...... el, randomised, phase 2 trial.
@en
prefLabel
Irinotecan-temozolomide with t ...... el, randomised, phase 2 trial.
@ast
Irinotecan-temozolomide with t ...... el, randomised, phase 2 trial.
@en
P2093
P2860
P1433
P1476
Irinotecan-temozolomide with t ...... el, randomised, phase 2 trial.
@en
P2093
Arlene Naranjo
Collin Van Ryn
John M Maris
Julia G Bender
Julie R Park
Marguerite T Parisi
Mitchell B Diccianni
Paul M Sondel
Rajen Mody
Rochelle Bagatell
P2860
P304
P356
10.1016/S1470-2045(17)30355-8
P577
2017-05-23T00:00:00Z